secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2026-05-14T11:08:04+00:00
Accession:  0001919246-26-000071
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos Therapeutics Q1 2026 ZELSUVMI net revenue $10.7M, up 17% QoQ; net loss $10.2M
--------------------------------------------------------------------------------

- ZELSUVMI net product revenue $10.7M in Q1 2026, up 17% from $9.1M in Q4 2025; units dispensed 7,884 (+25% QoQ).
- Net loss of $(10.2)M vs $(21.7)M in Q4 2025; adjusted EBITDA $(8.0)M.
- Cash $32.0M as of March 31, 2026; drew $30M from $50M Horizon term loan facility in January 2026.
- Sales force expanded to 64 territory managers from 50; April units 3,776; cumulative >20,000 since July 2025 launch.
- Planned commercialization of XEPI in early 2027 and XEGLYZE in mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000071/0001919246-26-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000071/pths-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001919246-26-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer